CeriBell (NASDAQ:CBLL) CTO Sells 4,887 Shares of Company Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 4,887 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $26.96, for a total transaction of $131,753.52. Following the sale, the chief technology officer directly owned 203,118 shares in the company, valued at approximately $5,476,061.28. The trade was a 2.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Raymond Woo also recently made the following trade(s):

• On Thursday, October 1st, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.38, for a total transaction of $119,145.06.
• On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The shares were sold at an average price of $24.33, for a total value of $118,900.71.
• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total value of $47,535.58.

CeriBell Trading Down 2.7%

Shares of CeriBell stock traded down $0.78 on Wednesday, hitting $27.50. The stock had a trading volume of 683,154 shares, compared to its average volume of 367,620. The stock has a 50 day moving average of $25.06 and a 200 day moving average of $20.85. The firm has a market capitalization of $1.06 billion, a P/E ratio of -15.63 and a beta of 0.86. CeriBell, Inc. has a twelve month low of $10.94 and a twelve month high of $28.89. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. The business had revenue of $29.34 million for the quarter, compared to analyst estimates of $29.18 million. Sell-side analysts expect that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CeriBell

Several large investors have recently modified their holdings of CBLL. BlackRock Inc. bought a new position in shares of CeriBell in the 2nd quarter worth about $37,657,000. Bank of New York Mellon Corp acquired a new position in shares of CeriBell in the 2nd quarter valued at about $17,437,000. TimesSquare Capital Management LLC acquired a new position in shares of CeriBell in the 2nd quarter valued at about $15,182,000. KCM Capital Inc boosted its position in shares of CeriBell by 40.0% during the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after purchasing an additional 400,000 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of CeriBell during the 2nd quarter valued at about $4,619,000.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Canaccord Genuity Group boosted their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. TD Cowen raised their target price on CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Barclays raised CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Raymond James Financial reiterated a “strong-buy” rating and issued a $29.00 price target on shares of CeriBell in a research report on Thursday, September 3rd. Finally, BTIG Research reissued a “buy” rating on shares of CeriBell in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.00.

Key Stories Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: CeriBell commercially launched a delirium-monitoring solution, expanding its point-of-care brain-monitoring platform and adding a new potential source of revenue. Article: Ceribell Expands Its Point-of-Care Brain Monitoring Platform
• Positive Sentiment: Third-quarter revenue was $29.34 million, slightly ahead of analysts’ $29.18 million estimate. Zacks reported a loss of $0.48 per share versus its $0.50 consensus loss estimate. Article: CeriBell Reports Q3 Loss, Tops Revenue Estimates
• Negative Sentiment: The company reported a $21 million quarterly loss, with new-launch expenses contributing to the higher loss. Its reported EPS of -$0.55 missed the consensus estimate of -$0.51, while the per-share loss worsened from $0.37 a year earlier. Article: CeriBell Posts Higher Q3 Loss With New Launch Expenses
• Negative Sentiment: CTO Raymond Woo sold 4,887 shares for about $132,000. The sale reduced his holdings by 2.35%, though he retained 203,118 shares. SEC insider transaction filing

About CeriBell

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.